Immunovant (IMVT) Operating Expenses (2018 - 2026)

Immunovant has reported Operating Expenses for 9 years, with the latest figure at $159.6 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 40.17% year-over-year to $159.6 million; the trailing twelve-month figure through Mar 2026 stood at $532.9 million (up 21.63% YoY), and the FY2026 full-year result was $532.9 million, up 21.62% from the prior year.
• Operating Expenses for Q1 2026 stood at $159.6 million, up from $114.4 million in the prior quarter.
• The five-year high for Operating Expenses was $159.6 million in Q1 2026, with the low at $40.4 million in Q2 2022.
• Historically, Operating Expenses has averaged $89.4 million across 5 years, with a median of $80.9 million in 2024.
• The largest YoY upside for Operating Expenses was 94.37% in 2023 against a maximum downside of 3.86% in 2023.
• Immunovant's Operating Expenses stood at $64.0 million in 2022, then slipped by 3.86% to $61.6 million in 2023, then jumped by 85.7% to $114.3 million in 2024, then increased by 0.05% to $114.4 million in 2025, then jumped by 39.52% to $159.6 million in 2026.
• The last three Operating Expenses figures came in at $159.6 million (Q1 2026), $114.4 million (Q4 2025), and $131.8 million (Q3 2025), per Business Quant data.